Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial

What Was Tested

This randomized controlled trial paper looks at Semaglutide.

Oral semaglutide is the first oral formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist developed for the treatment of type 2 diabetes.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

In this 52-week, multicentre, randomised, open-label, phase 3a trial, the researchers recruited patients with type 2 diabetes from 81 sites in ten countries.

How the Study Was Run

The design is described as randomized, open-label and multicenter.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Everyone knew when Semaglutide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

More than one site took part, so the participants came from several places.

This trial is registered with ClinicalTrials.gov, number NCT02849080, and European Clinical Trials Database, EudraCT number 2015-005593-38, and an open-label extension is ongoing.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents, Sitagliptin Phosphate, Glucagon-Like Peptide-1 Receptor Agonists and Semaglutide.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Semaglutide.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (The lancet. Diabetes & endocrinology), a journal based in England.

More context: the Semaglutide compound page.